Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

An open-label, multi-center Phase 2 study to assess the safety and efficacy of burixafor (GPC-100) and propranolol with G-CSF for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMuthalagu RamanathanGSGunjan L. ShahHSHyung C. Suh

Discussion

Loading...

Member takes

Overview

Open-label trial shows safe mobilization of hematopoietic progenitor cells in multiple myeloma, suggesting new treatment strategies.

Key Points

  • To assess the safety and efficacy of burixafor and propranolol with G-CSF for mobilizing hematopoietic progenitor cells in multiple myeloma patients eligible for AHCT.
  • Open-label, multi-center Phase 2 trial
  • Enrolled up to 20 participants across 10 sites
  • Administered propranolol and G-CSF, followed by burixafor before leukapheresis
  • Monitored safety for 28 to 100 days post-burixafor
  • All patients met primary endpoint, collecting ≥2x106 CD34+ cells/kg
  • 70% achieved ≥5x106 CD34+ cells/kg
  • Reported 277 adverse events, mostly grades 1 and 2
  • No serious infusion reactions were observed
  • All patients proceeded to AHCT within median of 12.5 days

Cite This Study

Ramanathan et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d759https://doi.org/10.1182/blood-2025-1050
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of motixafortide plus G-CSF versus plerixafor plus G-CSF for stem cell mobilization and collection in multiple myeloma: A single-center comparative analysis and interim Results from a prospective study in poor mobilizers2025
  2. 2Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy2025
  3. 3Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial2025
  4. 4Improved hematopoietic stem cell mobilization for gene therapy using single agent motixafortide in sickle cell disease2025
  5. 5Outcomes of upfront plerixafor use for mobilization in germ cell tumor patients2024